GeneDx Holdings investors who bought shares between April 16, 2025 and May 4, 2026 face an August 3, 2026 deadline to seek appointment as lead plaintiff in securities class-action litigation alleging the company and certain executives misled investors about the Fabric Genomics acquisition and its expected benefits. The claims gained attention after GeneDx reported first-quarter 2026 results on May 4, 2026, including a roughly $31.2 million to $31.3 million impairment tied to Fabric Genomics, a sharp increase in net loss, a decline in adjusted gross margin to 69% from 74%, softer recurring-revenue trends, and reduced 2026 guidance; GeneDx shares fell more than 49% the next day, according to the complaints and law-firm releases.